A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
NCT04036461
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
47
Enrollment
INDUSTRY
Sponsor class
Stopped
Slow accrual
Conditions
Multiple Myeloma
Interventions
DRUG:
CC-99712
DRUG:
BMS-986405
Sponsor
Celgene